CagriSema Research

Secher A, Lutz TA, Raun K

Amylin is a glucoregulatory peptide hormone discovered in 1986. Almost 20 years later, pramlintide, a human amylin analogue, emerged as the first amylin-based drug, approved as an adjunct treatment to insulin for type 1 diabetes (T1D) and type 2 diabetes (T2D). Despite its effects on multiple org...

Catalfamo VJ, Farhud S, Mulkey J, Lavie CJ

As the obesity epidemic expands, the alarming acceleration of youth obesity represents a critical global health concern. This timely analysis explores the underlying biological and socio-environmental drivers of childhood obesity and evaluates its role in the growing incidence of cardiometabolic ...

Muhundan M, Dash S

The prevalence of obesity continues to rise, with notable increase in stage III obesity in North America. The accumulation of excess adipose tissue can impair health with cardiovascular disease being the leading cause for increased mortality in people with obesity. The chronicity of the condition...

Carbone S, Billingsley HE, Ahmed SI, Golino M, Van Tassell BW, Markley R et al.

Alebna PL, Martey S, Mehta A, Lavie CJ, Carbone S

While excess adiposity is a known risk factor for incident heart failure ( HF), once the condition is established, observational data suggest that increased body mass index (BMI) may confer a survival advantage. This paradox has emphasized the underlying roles of cardiorespiratory fitness (CRF), ...

Sillassen CDB, Faltermeier P, Petersen JJ, Kamp CB, Grand J, Dominguez H et al.

Cardiovascular diseases, overweight, type 2 diabetes and chronic kidney disease increase the risk of cardiovascular events.Glucagon-like peptide-1 analogues are recommended by the European Society of Cardiology and the American College of Cardiology to lower the risk of death and progression of c...

Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, Ahmed EO, Mohamed AN et al.

Obesity has emerged as a pressing global health challenge, and therapies based on glucagon-like Peptide 1 receptor agonists (GLP-1RAs) have transformed its management. Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-labe...

Mehta M, Rometo D, Gusenoff J, Rubin JP

With obesity affecting over 40% of U.S. adults, bariatric surgery (BS) has become a cornerstone treatment, leading to massive weight loss (MWL) but also significant nutritional challenges. As demand for body contouring surgery (BCS) grows among post-BS patients, plastic surgeons must understand h...

Verma S, Böttcher M, Brown P, Dicker D, Rubino D, Sbraccia P et al.

Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo.The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body m...

Cho YK, Jung CH

Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders. Despite the significant benefits in glycemic control and weig...

Davies MJ, Broholm C, Garvey WT

Garvey WT, Osorto Contreras CK, Davies MJ

Chi H, Yang H, Deng Y

Lnu V, Noor F

Krakauer JC, Krakauer NY

Fogacci F, Cicero AFG

Al-Harbi FA, Alsaif AK, Almutairi AG, Alshehri HJ, Aleidan EA, Alabdulaaly GS et al.

Amylin-pathway therapies represent a novel therapeutic class for obesity and type 2 diabetes, however head-to-head comparative data and long-term outcome predictions remain limited. We conducted target trial emulation and computational predictive modeling aiming to predict future trial outcomes a...

Muskiet MHA, Nardone M, Rensen PCN, Cherney DZI, Cooper ME

We hypothesise that amylin receptor agonists (eg, pramlintide) and dual amylin and calcitonin-receptor agonists (eg, cagrilintide), which are emerging treatments for obesity and type 2 diabetes, can activate the renin-angiotensin system (RAS) and potentially undermine the cardiorenal benefits of ...

Son JW, le Roux CW, Blüher M, Nauck MA, Lim S

The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel GLP-1-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-enter...

Agarwal A, Padwal R, ACP Journal Club Editorial Team at McMaster University

GIM/FP/GP: [Formula: see text].